Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
412.23
-2.45 (-0.59%)
At close: Aug 25, 2025, 4:00 PM
417.10
+4.87 (1.18%)
After-hours: Aug 25, 2025, 7:46 PM EDT

Company Description

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees528
CEOWilliam Sibold

Contact Details

Address:
Four Tower Bridge, Suite 200
West Conshohocken, Pennsylvania 19428
United States
Phone267 824 2827
Websitemadrigalpharma.com

Stock Details

Ticker SymbolMDGL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001157601
CUSIP Number558868105
ISIN NumberUS5588681057
SIC Code2834

Key Executives

NamePosition
William J. SiboldChief Executive Officer, President and Director
Dr. Rebecca A. Taub M.D.Founder, Senior Scientific and Medical Advisor and Director
Mardi C. DierExecutive Vice President and Chief Financial Officer
Shannon KelleyExecutive Vice President, Chief Legal Officer and Corporate Secretary
Carole HuntsmanExecutive Vice President and Chief Commercial Officer
Mark UnderwoodExecutive Vice President of Business Planning and Operations
Ronald FilippoExecutive Vice President and Chief Information Officer
Tina E. VenturaChief Investor Relations Officer
Clint WallaceExecutive Vice President and Chief Human Resources Officer
Edward ChiangSenior Vice President of Clinical and Technical Operations

Latest SEC Filings

DateTypeTitle
Aug 21, 2025144Filing
Aug 20, 2025144Filing
Aug 18, 2025144Filing
Aug 18, 2025144Filing
Aug 15, 2025144Filing
Aug 15, 2025144Filing
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 13, 2025144Filing
Aug 12, 2025144Filing
Aug 12, 2025144Filing